Association between dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists and COVID-19 infection and adverse outcomes: a cohort study

Association between dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists and COVID-19 infection and adverse outcomes: a cohort study

Introduction People with type 2 diabetes (T2DM) have an elevated risk of adverse outcomes from COVID-19. Dipeptidyl peptidase-4 inhibitors (DPP4is) and glucagon-like peptide-1 receptor agonists (GLP1RAs) might have favorable effects on COVID-19 outcomes.Research design and methods We conducted a pop...

Full description

Saved in:
Bibliographic Details
Main Authors: Douglas S Lee, Peter C Austin, Michael E Farkouh, Cynthia A Jackevicius, Jeffrey C Kwong, Bing Yu, Heather Ross, Jiming Fang, Joan Porter, Vladimír Džavík, Alanna Weisman, Andrea S Gershon, Wade Thompson, Jacob A Udell, Clare L Atzema, Laura E Ferreira-Legere, Andrew Ha
Format: Article
Language:English
Published: BMJ Publishing Group 2025-08-01
Series:BMJ Open Diabetes Research & Care
Online Access:https://drc.bmj.com/content/13/4/e004677.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://drc.bmj.com/content/13/4/e004677.full

Similar Items